If your child still wets the bed regularly despite being school-age, you're not alone—and there may be new treatment options worth exploring. A recent study from China looked at how a medication called mirabegron, when combined with other therapies, affects children with non-monosymptomatic nocturnal enuresis (NMNE)—the medical term for bedwetting that happens alongside other daytime bladder problems.
What the researchers found
Doctors treated 31 children with a combination approach that included mirabegron, a medication that helps relax the bladder muscle and increase its capacity. After 12 weeks of treatment, the results were encouraging: children had fewer bedwetting episodes, fewer daytime accidents, and their bladders could hold more urine. Most impressively, 28 out of 31 children (90.3%) showed meaningful improvement in their bedwetting.
When researchers measured the children's bladders using special tests (urodynamic studies), they found that the bladder was functioning better—it could hold more and was less tense. Importantly, no serious side effects were reported during the study.
Important context: It's not the full picture yet
Before you rush to your paediatrician, it's important to understand what this study does and doesn't tell us. The researchers themselves emphasize that this was a preliminary study—it looked back at medical records rather than carefully testing mirabegron against other treatments. Because the children received several therapies at once (not just mirabegron), researchers cannot say for certain how much improvement came from the medication itself versus other parts of the treatment plan.
Think of this as early-stage evidence that's encouraging but not yet conclusive. It's like hearing about a promising new recipe—it sounds great, but you'll want to see it tested more rigorously before making it your go-to meal.
What this means for Singapore and Asian families
Bedwetting affects around 15% of 5-year-olds in Singapore and other developed Asian countries, and it can persist into the teen years for some children. For families dealing with this issue, finding effective treatments matters—not just for hygiene, but for a child's confidence and quality of life.
This research suggests that mirabegron could eventually become part of a toolkit for treating children whose bedwetting is linked to a small bladder capacity or overactive bladder muscles. However, Singapore parents should know that more rigorous research is still needed, and any treatment should be supervised by a paediatrician or specialist who can assess your child's individual situation.
Three practical next steps for parents
- Start with the basics first. Before exploring medication, ensure your child is using evidence-based approaches like bladder training, scheduled toilet visits, limiting evening fluids, and using bedwetting alarms if appropriate. These should always be the first step and work for many children.
- Get a proper assessment. If your child's bedwetting persists despite these measures, ask your doctor for a referral to a paediatrician or urologist who can identify the underlying cause—whether it's a small bladder capacity, overactive bladder, or other factors. This diagnosis will guide the right treatment.
- Keep an open conversation with your specialist about new options. While mirabegron-containing treatments show promise in early research, they're not yet standard practice. Discuss with your child's doctor whether this approach might be worth considering for your child, and what the realistic timeline for improvement looks like.